Please assess the completion status of the following clinical trial:

Trial Title: Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient must be able to understand and communicate with the Investigator and comply with the requirements of the study and must provide written, signed and dated informed consent before any study assessment is performed.~2. Male or female patients at least 18 years of age.~3. Diagnosis of PsA as per CASPAR with active PsA for at least 6 months and a TJC ≥ 3 of 78 and SJC ≥ 3 of 76 at Baseline.~4. Patients must have a total synovitis PDUS score ≥ 2 and inflammation related to PD signal ≥ 1 for at least 2 (affected joints as observed via PDUS) of 48 joints at the Screening visit and at the Baseline visit (before infusion).~5. At least 1 clinically-involved enthesitis site at Screening and at the Baseline visit (before infusion) defined by SPARCC index different from 0.~Exclusion Criteria:~1. Chest X-ray or chest MRI with evidence of ongoing infectious or malignant process obtained within 3 months prior to Screening and evaluated by a qualified physician.~2. Previous exposure to secukinumab or other biologic drug directly targeting IL-17 or IL-17 receptor.~3. Any change in the dose of oral corticosteroids in the last 4 weeks prior to the Baseline visit or use of i.v. intramuscular or intra-articular corticosteroid during the last 4 weeks prior to the enrollment visit.~4. Patients who have previously been treated with TNFα inhibitors (investigational or approved).~5. History of hypersensitivity to the study drug or its excipients or to drugs of similar classes.~6. Previous treatment with any cell-depleting therapies including but not limited to anti CD20 investigational agents (e.g. CAMPATH, anti-CD4, anti-CD5, anti-CD3, anti CD19).~7. Prohibited psoriasis treatments/medications with topical corticosteroids in the last 4 weeks prior to randomization.~8. Pregnant or nursing (lactating) women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: ACTIVE_COMPARATOR): In Treatment Period-1:~Patients in this group were administered secukinumab with 12 weeks of treatment from baseline.~In Treatment Period-2:~Patients continued to receive the same active dose of secukinumab every 4 weeks until Week 24~In Treatment Period 3 (extension period):~the extension period allowed responder patients the possibility to continue open-label secukinumab treatment up to Week 52
- Group 2 (Type: PLACEBO_COMPARATOR): In Treatment Period-1:~Patients received placebo at baseline and same time points as secukinumab until Week 8.~In Treatment Period-2:~Patients commenced open-label secukinumab every 4 weeks from Week 12, as follows, based on their clinical characteristics at Week 12~In Treatment Period-3:~Open-label secukinumab continued to be assigned to patients

Based on this trial design, predict the completion outcome and termination type (if applicable).